Clinical Trial Update: A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 trial of a novel compound for excessive daytime sleepiness in narcolepsy; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Narcolepsy

Drugs mentioned

• Pfizer investigational compound

Snippet

Sponsor: Pfizer | Conditions: Excessive Daytime Sleepiness, Narcolepsy | Phase 2 | Status: COMPLETED | Results posted: 2014-05-09